On Invalid Date, Transcode Therapeutics (NASDAQ: RNAZ) reported Q3 2023 earnings per share (EPS) of -$67.20, up 74.58% year over year. Total Transcode Therapeutics earnings for the quarter were -$5.30 million. In the same quarter last year, Transcode Therapeutics's earnings per share (EPS) was -$264.40.
As of Q1 2024, Transcode Therapeutics's earnings has grown year over year. Transcode Therapeutics's earnings in the past year totalled -$19.59 million.
What was RNAZ's revenue last quarter?
On Invalid Date, Transcode Therapeutics (NASDAQ: RNAZ) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Transcode Therapeutics's revenue was $0.00.
What was RNAZ's revenue growth in the past year?
As of Q1 2024, Transcode Therapeutics's revenue has grown null year over year. Transcode Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.